This study investigated the toxic effects of silver on the kidneys and livers of Sprague-Dawley rats after administering multiple doses of silver nanoparticles synthesized using extracts of Cinnamomum cassia (CcAgNPs). Twenty-four Sprague-Dawley rats (250 +/- 20 g) were randomly assigned to four groups (A-D) of six animals per group and treated for 8 weeks. Group A was administered 200 mg/kg of Cinnamon Cassia extract (Cc), group B 5 mg/kg of CcAgNPs, group C 10 mg/kg of CcAgNPs, and group D normal saline. Body weight was measured weekly and fasting blood glucose was measured fortnightly. At the end of the experiment, animals were euthanized and organs (livers and kidneys) were fixed in neutral buffered formalin and processed for light microscopy (H&E). Body weight differences were significantly higher (P < 0.05) in the low-dose Cc group and the kidney to body weight ratio was not significant. Renal function analysis of proteins and ketones showed a significant increase in CcAgNP-treated rats (P < 0.05). Kidney and liver histology showed distortions in hepatocytes and sinusoidal linings with infiltrations especially in the higher dose groups. Kidney histology mirrored degenerative changes in glomerular and Bowman's capsules with fibrillary mesangial interstitium. CcAgNPs impairs renal and hepatic morphology and function after a long period of administration.
Over a decade after artemisinin-based combination therapy (ACT) approval as the most preferred anti-malarial drug. Seven ACTs can be sourced as over-the-counter medications in most African pharmacies without prescription. A comparative neurotoxicity of these ACTs was investigated in an in vivo experimental model. Swiss mice numbering 40, weighing 18 - 26 g were allotted to eight groups (n = 5). Group 1 (normal control [NC]), received distilled water 10 mL, while groups 2 to 8 were administered (5.71 mg artesunate+amodiaquine [AA]); (19.29 mg artesunate+mefloquine [AM]); (10.36 mg artesunate+sulfadoxine+pyrimethamine [ASP]); (19.29 mg artesunate+pyronaridine [APy]); (12.5 mg artemisinin+piperaquine [AP]); (15.42 mg dihydroartemisinin+piperaquine [DP]); and (8 mg artemether+lumefantrine [AL]) per kg body weights, respectively orally for 3 days, but for 2 days in group 6. Animals were sacrificed 24 hrs after last administration under ketamine anaesthesia (100 mg/kg, i.p), and excised brains were evaluated for neurochemical and neurohistological alterations. Oxidative stress markers: malondialdehyde and reduced glutathione significantly (p < 0.05) increased as well as antioxidant enzymes glutathione peroxidase, catalase, superoxide dismutase in ACT-administered groups compared to NC. Neurohistology of hippocampal cornu ammonis 1 (CA1) and cerebellum demonstrated vacuolations, neuronal hypertrophy and atrophy pyramidal, and Purkinje neurons. Immunohistochemistry with glial fibrillary acidic protein antibody demonstrated mild to mostly severe astrogliosis in the ACT-administered groups. In conclusion, oxidative stress markers and antioxidants were elevated in the order DP>APy>AP>ASP>AA>AL>AM. Together with the neurohistology, neurotoxicity were in the order DP>ASP>APy>AP>AL>AA>AM particularly in the hippocampus compared to the cerebellum. KEYWORDS: Artemisinin-based combination therapies, Cerebellum, CA1 region of the hippocampus, Neurodegeneration, Oxidative stress.
31 August 2016 in Asian Journal of Medical Sciences
Background: Efavirenz is a drug used in combination as highly active antiretroviral therapy (HAART) used for the treatment of human immunodeficiency virus (HIV).Aims and Objectives: To investigate the effects of Efavirenz and vitamin E on the histopathology and biochemical parameters in the liver of Wistar rats.Materials and Methods: Twenty five Wistar rats were divided into fi ve groups. Group A were administered with 1 ml of distil water; group B animals were administered with 8.57 mg/kg Efavirenz, group C were administered with 17.14 mg/kg Efavirenz; group D were administered with 8.57 mg/kg, Efavirenz and 14.82 mg/kg Vitamin E, and group E were administered with 14.82 mg/kg Vitamin E for 32 days. On day 33, the rats were sacrificed using chloroform inhalation method. The liver were excised, routinely processed, stained using haematoxylin and eosin method, and viewed in DPX medium under light microscope. Blood samples from the rats were collected and then centrifuged after 30 minutes to obtain the serum for analysis of aspartate amino transaminase (AST), alanine amino transaminase (ALT), alkaline phosphatase (ALP), and total bilirubin (TB).Results: The liver of Wistar rats administered with Efavirenz, showed distortions with various degree of vacoulations, dilatation of sinusoidal spaces and nuclei pyknoctic changes. In the group where Efavirenz was combined with vitamin E this changes were ameliorated. This also agreed with the biochemical changes which showed significant levels of increase in AST and ALT in Efavirenz groups, this changes were also ameliorated in the group that Efavirenz was combined with vitamin E.Conclusion: Efavirenz administration can damage the liver, vitamin E can ameliorate this effect, therefore Vitamin E should be prescribed for patients on Efavirenz administration.Asian Journal of Medical Sciences Vol.7(5) 2016 81-86